Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.

Doctor in mask helping lady with a respiratory oxygen mask sitting on hospital bed

Many people recovering from COVID-19 suffer from long-term symptoms of lung damage, including breathlessness, coughing, fatigue and limited ability to exercise.

COVID-19 can lead to inflammation in the lungs due to the infection and the immune system’s reaction to it. The inflammation may improve over time, but in some people it persists.

In severe cases, the lungs may become scarred. The scarring causes stiffness in the lungs, which can make it difficult to breathe and get oxygen to the bloodstream, resulting in long-term breathlessness and difficulty managing daily tasks.

This inflammation and scarring of the lungs is called ‘interstitial lung disease’.

Now, this study, called the UK Interstitial Lung Disease Long-COVID19 (UKILD-Long COVID) study, will investigate whether post-COVID-19 lung damage will improve or worsen over time, how long it will last, and the best strategies for developing treatments.

Read the full story on the NIHR Oxford Biomedical Research Centre website